Medivir has determined the starting dose for the next part of the phase Ib study with MIV-818
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient has undergone the safety follow-up to identify potentially dose-limiting toxicity from the first part of the phase Ib study with the company's leading candidate drug, MIV-818, against liver cancer. The results were positive and the recommended dose for the next phase has thus been determined. At present, three patients continue to be active on treatment within the study, and they will continue treatment until intolerable side effects or disease progression occur. The second part of the phase Ib